Synpromics wins best emerging UK synthetic biotech company at OBN Awards
Edinburgh, UK, 6th October 2017 / Sciad Newswire / Synpromics is thrilled to announce they have been awarded Best Emerging UK Synthetic Biotech Company at the 9th Annual OBN Awards celebration last night. Synpromics was nominated on the strength of being the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design.
The OBN Awards celebrate innovation and outstanding achievement across the UK Life Sciences industry, including emerging to late-stage R&D companies as well as life science investors. The Awards cover Biotech, Medtech, Synthetic Biology and Digital Health.
Receiving the award, Michael Roberts, Founder & CSO of Synpromics, commented: ‘We could not be happier with the outcome of last night’s Awards. This accolade is testament to the significant progress we have made over the past year, in growing our business by expanding the number of partnerships that we have with top pharma and biotech companies and significantly expanding our team.’
Synpromics would like to thank OBN for organising The Awards, and SynbiCITE for sponsoring this award.
For further information, contact
Dr Michael Roberts, CSO
T: +44 (0)131 651 9667
Deborah Cockerill / Emma Pickup
Sciad Communications Ltd
T: +44 (0)20 7470 8801
Notes to Editors
Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design. The Company has developed PromPT™, its multi-dimensional bioinformatics database that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications.
The company operates in a diverse range of fields, including broad applications in cell and gene based medicine, biologics manufacturing and viral vector bioprocessing. Current partners include Adverum, uniQure, AGTC, GE Healthcare, and Sartorius-Stedim Cellca as well as numerous undisclosed partners in the pharmaceutical sector.
About synthetic promoters
Naturally occurring promoters have evolved for biological functions but have limitations when utilised in industrial or therapeutic applications. Synthetic promoters with DNA sequences not found in nature are designed to better regulate gene activity and precisely control protein production. Synpromics creates highly specific promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. Each synthetic promoter represents a novel invention and thus can be patented.
For more information visit www.synpromics.com
Got an innovation you need bringing to life?
We’d love to hear from you! Head to our contact page to start a conversation.